Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Label Study of the Poly(ADP-ribose) Polymerase Inhibitor Niraparib in Monotherapy or in Combination With Anti-PD1 Inhibitor TSR-042 in Recurrent Endometrial Cancer

NCT03016338 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT03016338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03016338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Label Study of the Poly(ADP-ribose) Polymerase Inhibitor Niraparib in Monotherapy or in Combination With Anti-PD1 Inhibitor TSR-042 in Recurrent Endometrial Cancer
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 6, 2017
Completion date
December 31, 2026
Enrollment
51 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer